Partial EMT takes the lead in cancer metastasis

Jef Haerinck; Geert Berx

doi:10.1016/j.devcel.2021.11.012

Partial EMT takes the lead in cancer metastasis

Dev Cell. 2021 Dec 6;56(23):3174-3176. doi: 10.1016/j.devcel.2021.11.012.

Authors

Jef Haerinck¹, Geert Berx²

Affiliations

¹ Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
² Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium. Electronic address: geert.berx@ugent.be.

PMID: 34875220
DOI: 10.1016/j.devcel.2021.11.012

Abstract

In this issue of Developmental Cell, Lüönd et al. developed a tracing system, using the uncharacterized early epithelial-mesenchymal transition (EMT)-marker Tenascin C, to monitor cells undergoing partial EMT during malignant mammary cancer progression. They find that partial, but not full, EMT contributes to metastasis and that full EMT contributes to chemoresistance.

Publication types

Comment

MeSH terms

Epithelial-Mesenchymal Transition*
Neoplasms*